Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China
Shots:
- Cullinan will receive $20M up front and is eligible to receive ~$211M in development- regulatory and sales-based milestone payments
- Cullinan is also eligible for high-single-digit to low-teen tiered royalties based on sales of CLN-081 in Greater China includes Hong Kong- Macau and Taiwan
- CLN-081 is an orally available- small-molecule- irreversible EGFR inhibitor- which is currently in P-I/IIa dose escalation and expansion trial for NSCLC patients
Ref: GlobeNewswire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
